{'fraction_non_alphanumeric': 0.01991465149359886, 'fraction_numerical': 0.00995732574679943, 'mean_word_length': 5.121739130434783, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Management of scleroderma-related end-stage renal disease with automated peritoneal dialysis.

Kidney failure is the principal cause of death in scleroderma and accounts for at least 50% of deaths in this disease. Management of scleroderma-related end-stage renal disease requires some form of renal replacement therapy. Survival up to 18 months has been reported in one patient on continuous ambulatory peritoneal dialysis. Surviving for more than 1 year on automated peritoneal dialysis has not been reported. We report a patient with scleroderma-related end-stage renal disease treated with automated peritoneal dialysis with steady state control of uremia and hypertension at 18 months of follow-up.